Lin Yun, Jiang Wenjie, Ma Lihua, Zhang Jiayu, Tang Ye, Kan Qiuqi, Xiong Haifeng, Wu Jiayan, Zhang Jun, Niu Yiwen, Zhang Wei, Wang Shengnan, Wang Weikang, Xie Quan, Li Tuofan, Wan Zhimin, Gao Wei, Shao Hongxia, Qin Aijian, Ye Jianqiang
Key Laboratory of Jiangsu Preventive Veterinary Medicine, Key Laboratory for Avian Preventive Medicine, Ministry of Education, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China.
Vaccines (Basel). 2024 Nov 30;12(12):1357. doi: 10.3390/vaccines12121357.
Duck adenovirus 3 (DAdV-3) is an emerging pathogen that has caused severe economic losses to the duck industry in China. Recently, the infection of ducks with serotype 4 fowl adenovirus (FAdV-4) has also been reported in China. Therefore, an efficient bivalent vaccine to control the diseases caused by DAdV-3 and FAdV-4 is extremely urgent. In our previous study, a recombinant FAdV-4 expressing Fiber-2 of DAdV-3 was generated and designated as rFAdV-4-Fiber-2/DAdV-3.
Here, the recombinant virus rFAdV-4-Fiber-2/DAdV-3 was inactivated to serve as a bivalent vaccine, and its immunogenicity and protective efficacy against DAdV-3 were evaluated in Muscovy ducks.
The subcutaneous injection of rFAdV-4-Fiber-2/DAdV-3 could efficiently induce antibodies against Fiber-2 of DAdV-3 and neutralize antibodies against FAdV-4. After challenges with DAdV-3, in comparison with the non-immunized ducks, the immunized ducks did not show any bodyweight loss, gross lesions, or histopathologic change. Moreover, viral loads in livers and kidneys from immunized ducks were undetectable, whereas those in non-immunized ducks with challenge were significantly high.
All these data demonstrate that the inactivated recombinant virus rFAdV-4-Fiber-2/DAdV-3 has the potential to be an efficient vaccine candidate against both FAdV-4 and DAdV-3, although efficacy for FAdV-4 needs to be confirmed experimentally.
鸭腺病毒3型(DAdV-3)是一种新出现的病原体,已给中国鸭业造成严重经济损失。最近,中国也报道了鸭感染4型禽腺病毒(FAdV-4)的情况。因此,研发一种高效的二价疫苗来控制由DAdV-3和FAdV-4引起的疾病迫在眉睫。在我们之前的研究中,构建了一种表达DAdV-3纤维蛋白-2的重组FAdV-4,并命名为rFAdV-4-Fiber-2/DAdV-3。
在此,将重组病毒rFAdV-4-Fiber-2/DAdV-3灭活制成二价疫苗,并在番鸭中评估其免疫原性和对DAdV-3的保护效力。
皮下注射rFAdV-4-Fiber-2/DAdV-3可有效诱导针对DAdV-3纤维蛋白-2的抗体和针对FAdV-4的中和抗体。用DAdV-3攻毒后,与未免疫的鸭相比,免疫的鸭未出现任何体重减轻、肉眼可见病变或组织病理学变化。此外,免疫鸭肝脏和肾脏中的病毒载量检测不到,而攻毒的未免疫鸭的病毒载量则显著升高。
所有这些数据表明,灭活的重组病毒rFAdV-4-Fiber-2/DAdV-3有潜力成为一种针对FAdV-4和DAdV-3的高效候选疫苗,尽管FAdV-4的效力需要通过实验来证实。